Rabbit Recombinant Monoclonal TAK1 phospho S439 antibody. Carrier free. Suitable for IP, Dot, WB and reacts with Human, Synthetic peptide, Mouse, Rat samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
ICC/IF | IP | Flow Cyt | Dot | WB | IHC-P | |
---|---|---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Expected | Expected | Not recommended |
Mouse | Not recommended | Predicted | Not recommended | Predicted | Expected | Not recommended |
Rat | Not recommended | Predicted | Not recommended | Predicted | Expected | Not recommended |
Synthetic peptide | Not recommended | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Synthetic peptide | Dilution info - | Notes - |
Select an associated product type
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis (By similarity).
Mitogen-activated protein kinase kinase kinase 7, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1, TAK1, MAP3K7
Rabbit Recombinant Monoclonal TAK1 phospho S439 antibody. Carrier free. Suitable for IP, Dot, WB and reacts with Human, Synthetic peptide, Mouse, Rat samples.
Mitogen-activated protein kinase kinase kinase 7, Transforming growth factor-beta-activated kinase 1, TGF-beta-activated kinase 1, TAK1, MAP3K7
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
Yes
EPR2863
Affinity purification Protein A
This antibody only detects TAK1 phosphorylated at Serine 439 in Human or TAK1 phosphorylated at Serine 412 in Mouse.
Blue Ice
+4°C
Do Not Freeze
ab239974 is the carrier-free version of Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
TAK1 also known as MAP3K7 (Mitogen-activated protein kinase kinase kinase 7) is an important protein kinase that weighs approximately 63 kDa. This protein is expressed in various tissues and cells including HEK 293T cells. TAK1 plays a mechanical role as a part of the MAPK signaling cascade. It phosphorylates and activates downstream kinases which is key to transmitting cellular signals that regulate responses to external stimuli like cytokines and stress.
TAK1 is involved in several cellular processes necessary for maintaining balance and responding to stress. TAK1 forms a complex with proteins like TAB1 TAB2 and TAB3 which are important for its activation and signaling function. This complex facilitates TAK1's involvement in inflammation and immune response indicating its significance in mediating cellular survival and apoptosis.
TAK1 operates within the NF-κB and MAPK pathways two critical routes for cellular response to inflammation and stress. In the NF-κB pathway TAK1 activates IKK which triggers the degradation of IκB freeing NF-κB to move into the nucleus and activate transcription. In the MAPK pathway TAK1 directly influences JNK and p38 cascades revealing regulatory connections to proteins like MEK and ERK.
TAK1 has been linked to conditions such as cancer and inflammatory diseases. In cancers aberrant TAK1 activity can lead to enhanced cell proliferation and survival. Moreover inflammation-related disorders can arise from malfunctioning TAK1 signaling demonstrating its connection to proteins like TNF receptor-associated factors which are involved in inflammatory responses. Understanding TAK1's role in these disorders may pave the way for developing potential therapeutic interventions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Purified Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404 at 1/50 dilution (2μg) immunoprecipitating TAK1 in HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate 10μg
Lane 2 (+): Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404 + HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab239974 in HeLa treated with 100nM Calyculin A and 20ng/ml human IL-1 beta for 10min whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 75 kDa
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404).
All lanes: Immunoprecipitation - Anti-TAK1 (phospho S439) antibody [EPR2863] (Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404)
Predicted band size: 67 kDa
Observed band size: 80 kDa
Dot Blot analysis of Lane 1: TAK1 (phospho S439) phospho peptide and Lane 2: TAK1 non-phospho peptide labeling TAK1 (phospho S439) with Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404 at 1/1000 dilution (0.009 μg/ml). 5% NFDM/TBST was used as the diluting and blocking buffer. Goat Anti-Rabbit IgG H&L (HRP) ab97051 Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated was used as the secondary antibody at 1/100,000 dilution. Exposure time: 3 minutes.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-TAK1 (phospho S439) antibody [EPR2863] ab109404).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com